These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24377552)

  • 21. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
    Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
    Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
    Liu Q; Hilsenbeck S; Gazitt Y
    Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
    Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
    Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of secoisolariciresinol diglucoside combined with bortezomib on induction of apoptosis in lung cancer cell line A549].
    Li XW; Yang JR
    Zhong Yao Cai; 2012 Feb; 35(2):248-53. PubMed ID: 22822672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
    Abou-Merhi R; Khoriaty R; Arnoult D; El Hajj H; Dbouk H; Munier S; El-Sabban ME; Hermine O; Gessain A; de Thé H; Mahieux R; Bazarbachi A
    Leukemia; 2007 Aug; 21(8):1792-801. PubMed ID: 17568816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs.
    Meister MT; Boedicker C; Graab U; Hugle M; Hahn H; Klingebiel T; Fulda S
    Cancer Lett; 2016 Oct; 381(2):287-95. PubMed ID: 27521572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
    Lunghi P; Giuliani N; Mazzera L; Lombardi G; Ricca M; Corradi A; Cantoni AM; Salvatore L; Riccioni R; Costanzo A; Testa U; Levrero M; Rizzoli V; Bonati A
    Blood; 2008 Sep; 112(6):2450-62. PubMed ID: 18583568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
    Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
    Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
    Sharma M; Khan H; Thall PF; Orlowski RZ; Bassett RL; Shah N; Bashir Q; Parmar S; Wang M; Shah JJ; Hosing CM; Popat UR; Giralt SA; Champlin RE; Qazilbash MH
    Cancer; 2012 May; 118(9):2507-15. PubMed ID: 21887685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
    Li L; Meng FY; Fu YB; Cai YX; Sun QX
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1504-6. PubMed ID: 17959525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
    Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
    Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms.
    Wang X; Zhang M
    Mol Med Rep; 2015 Jul; 12(1):1449-56. PubMed ID: 25815518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
    Held LA; Rizzieri D; Long GD; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Horwitz ME; Chao NJ; Gasparetto C
    Cancer Invest; 2013 Mar; 31(3):172-6. PubMed ID: 23406188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
    Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Caspase-independent apoptosis induced by arsenic trioxide in human multiple myeloma cell RPMI8226].
    Xie J; Zhang M; Song YP; Hu K; Ren JJ; Zhang YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):107-11. PubMed ID: 22391177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo.
    Shen L; Zhang G; Lou Z; Xu G; Zhang G
    BMC Complement Altern Med; 2017 Feb; 17(1):106. PubMed ID: 28187727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
    Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G
    Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.